Muller, James, and Shin-Mey Rose Geist
The purpose of this table clinic is to raise the awareness that premature discontinuation of Plavix has caused catastrophic events of MI and/or death.
Plavix is an antiplatelet agent that inhibits platelet aggregation, thus preventing thrombus formation. Individuals who have high risk for myocardial infarction (MI) or cerebral vascular accident (stroke) are prescribed this medication to prevent cardiovascular events. Plavix is also prescribed to patients received coronary artery stents to prevent MI, and the current guideline recommends its use for 12 months following drug-eluting stent (DES) placement. Many dental patients take Plavix for the above mentioned reasons. Dentists‟ intuitive concern is increased risk of bleeding during and after the dental procedures. Their dilemma in treating these patients has been:
This table clinic provides the best available evidence on the risks and benefits of altering a patient‟s Plavix regimen. We also provide a strategy in assessing risk of bleeding and managing dental patients who are taking antiplatelet agents including Plavix.